BetterLife Announces Extension of Warrants
30 Noviembre 2023 - 7:00AM
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR
/ OTCQB: BETRF / FRA: NPAU), an emerging biotech company
focused on the development and commercialization of cutting-edge
treatments for mental disorders, announces that, effective December
1, 2023, the expiry date of 6,386,298 outstanding share purchase
warrants (“Warrants”) are extended to December 2, 2025.
These Warrants, with an original exercise price
of $0.60 and expiry date of December 2, 2023, were granted pursuant
to the exercise of the Company’s December 2020 private placement
offering of special warrants.
The Company will not issue new warrant
certificates in connection with the forementioned amendment.
Previously issued warrant certificates remain valid and enforceable
until the amended expiry date of December 2, 2025. Warrantholders
may exercise their warrants by returning a completed subscription
notice/form (included with the warrant certificate), the original
warrant certificate and payment by bank draft (made payable to
“BetterLife Pharma Inc.”) to the Company’s legal counsel at:
Alexander, Holburn, Beaudin + Lang LLP, #2700-700 West Georgia
Street, Vancouver, BC V7Y 1B8 (C/O BetterLife Pharma Inc.). For
warrant exercises that will be paid by wire transfer or any
questions related to the warrants, please contact
IR@BlifePharma.com.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging
biotechnology company primarily focused on developing and
commercializing two compounds, BETR-001 and BETR-002, to treat
neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and
IND-enabling studies, is a non-hallucinogenic and non-controlled
LSD derivative in development and it is unique in that it is
unregulated and therefore can be self-administered. BetterLife’s
synthesis patent for BETR-001 eliminates regulatory hurdles and its
pending patent, for composition and method of use, covers treatment
of major depressive disorder, anxiety disorder and neuropathic pain
and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and
IND-enabling studies, is based on honokiol, the active anxiolytic
ingredient of magnolia bark. BetterLife’s pending method of use and
formulations patent covers treatment of anxiety related disorders
including benzodiazepine dependency.
BetterLife also owns a drug candidate for the
treatment of viral infections such as COVID-19 and is in the
process of seeking strategic alternatives for further
development.
For further information, please
visit BetterLife Pharma.
BetterLife Pharma Inc. Contact
Information
David Melles, Investor Relations ManagerEmail:
David.Melles@blifepharma.comPhone: 1-778-887-1928
Cautionary Note Regarding
Forward-Looking Statements
No securities exchange has reviewed nor accepts
responsibility for the adequacy or accuracy of the content of this
news release. This news release contains forward-looking statements
relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not
historical facts. Forward-looking statements are often identified
by terms such as “will”, “may”, “should”, “anticipate”, “expects”
and similar expressions. All statements other than statements of
historical fact, included in this release are forward-looking
statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure to satisfy the conditions of the relevant
securities exchange(s) and other risks detailed from time to time
in the filings made by the Company with securities regulations. The
reader is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024